The myNEO platform focuses on detecting, identifying, and validating all alterations that have occurred in cells, and what their immunogenic impact is. The most effectual process wherein a cell undergoes genomic, transcriptomic, and epigenomic changes is during oncogenesis. Identifying per patient which alterations lay at the origin of the cancer cells and which have been accumulated during clonal expansion of the tumour is of high importance. Studying these alterations, their impact on the presented antigen repertoire on the cell’s surface, and the immunogenic implications has several important applications.
The primary therapeutic focus of our patient-specific tumour screening platform is personalised immunotherapy. A validated set of tumour-specific surface molecules is chosen and validated per patient. Via various cell-based and vaccination strategies, the patient’s own immune system is redirected against these chosen neoantigens. The software module is firmly integrated with experimental and clinical validation.
By performing the personalised analysis on a cohort of different samples, targets that are detected in a multitude of samples (‘shared immunogenic target discovery’) are used for off-the-shelf therapeutics. Big data analytics are used to identify alterations frequently shared amid patients and to explore other inter-patient associations.
myNEO Treatment Advisor
The tumour fingerprint is used to analyse specific mutations in genes or gene regions that have known or suspected associations with the prognosis of the patient, and to decide upon the optimal treatment plan. New (diagnostic) markers to improve therapy efficacy predictions and distinguish responders from non-responders in clinical trials are also actively sought after.